4baseCare has achieved a significant investor milestone by raising a total investment of ₹128 crore (approximately $13.3 million) during its current Series B funding round. This full infusion comprises a newly completed top-up funding injection of ₹38 crore. This latest capital injection was led by Infosys and growX Ventures. Additionally, a set of existing Venture Investors actively engaged in this top-up funding round, reinforcing their commitment to the company’s future growth.

Capital deployment and primary flagship

This latest financial infusion follows shortly after a significant earlier development, which took place only a few months ago, when the healthtech startup managed to complete the first tranche of the series B funding round. On that first close, the company had received an investment of ₹90 crore from a high-profile investment syndicate co-led by Ashish Kacholia, a veteran public market investor, and Lashit Sanghvi, along with their early-stage investor Yali Capital. The combined investment will ensure that the biomedical startup can quickly propel its core business, namely, to fill the unmet needs in medical genomics in serious global markets.

4baseCare’s corporate leadership team has outlined clear directives for the successful and effective allocation of the newly acquired capital reserves. A significant portion of the fresh financial resources will be used to aggressively expand its existing specialist network of genomics laboratories in various geographic markets. 

The startup is clearly making technological initiatives of its main AI infrastructure a priority. The organization seeks to advance these technical skills to finely tune its sophisticated diagnostics tools and create highly integrated health networks.

In addition to hardware and physical resources, a significant aspect of the company’s financial trajectory is dedicated to increasing access to healthcare for underrepresented communities. The startup will directly bring its precision oncology offerings to emerging global corridors spread across a vast geographical presence, including India, the Middle East, Southeast Asia, Latin America, and other developing market economies. The company aims to help address the ongoing lack of regional, annotated genetic information for precision therapeutics.

OncoTwin is the company’s sole flagship solution that represents its technological advances. The OncoTwin platform serves as a significant digital support tool for healthcare workers globally. 

The system is especially designed to offer practicing Oncologists valuable and actionable insights for difficult patient cases. To do this complex thing in a seamless way, it processes and synthesizes huge quantities of complex clinico-genomic data along with real-world, localized patient data. Combining these various data points, the platform enables medical teams to identify highly targeted therapies that significantly increase positive clinical outcomes.

Operational and ongoing scaling

4baseCare already operates with a highly diversified and well-developed infrastructure network. The precision healthcare startup operates active functional testing labs in geographies like India, Dubai, Nepal, and the Philippines. Plans for the expansion of the corporate footprint have picked up significantly. 

The business will aggressively build operations and seek to open in an additional 8-10 countries worldwide over the next 12-18 months. In addition to its international geographic expansion efforts, however, 4baseCare is actively pursuing its domestic business growth plans by building an innovative in-hospital genomics laboratory model. 

The strategy depends much on close institutional partnerships with top-tier medical centres and healthcare institutions. The company has already established major operating partnerships with leading hospital systems such as the All India Institute of Medical Sciences, Jammu; Max Healthcare; and Shankara Hospital.

The company’s continued expansion of its laboratory footprint and institutional partnerships is directly fueling large-scale commercial diagnostic test volumes. About 1,500 full genomes are processed and run per month at the precision oncology startup. Corporate usage of the business is actively scaling, as is the need to scale in-house capacity, with expected test volumes to grow as much as 8,000 to 10,000 tests per month.

This significant investment in capital is happening during a period of dramatically increased overall VC investment in medical startups focused on oncology. Competing enterprise Everhope Oncology raised $10 million in its first round of seed funding the prior year. 

MOC Cancer Care and Research Centre is in the midst of a major investment round, worth $18 million, that was led by Elevation Capital. Notable and currently funded startups within this competitive landscape include some of the newest inclusion health ventures running the show: ErlySign, OnCare and OneCell Diagnostics.

Conclusion

The funding of ₹128 crore in Series B is a remarkable milestone for 4baseCare, solidifying its position as a leader in the precision oncology space. The startup, supported by large investors like Infosys and GrowX Ventures, is well placed to help fill the global diversity deficit in cancer genomics and expand its lab operations to 8 to 10 additional countries. The company’s vision of transforming the delivery of high-value-added diagnostics from a luxury to a standard of care in emerging markets is being achieved by pairing its flagship AI Clinical Decision Platform, OncoTwin, with its most advanced, in-hospital clinical laboratories.

The substantial capital infusion will allow the business to remain a catalyst for medical innovation and expand its testing capabilities significantly, to enhance the efficacy of cancer treatment globally.